Press Centre
Press Releases
Notice of Results
Phynova Group plc
("Phynova" or "the Company")
Notice of Results
Phynova Group PLC (AIM: PYN), the developer of prescription pharmaceuticals derived from Chinese botanical medicines, advises that it will be announcing its Interim Results for the six months ended 31 March 2007 on Thursday 28 June 2007.
Analyst presentations will be given by the Company´s Management from 09:30 a.m. on Thursday 28 June 2007 at Abchurch Communications, 100 Cannon Street, London, EC4N 6EU.
- Ends -
For further information, please contact:
Phynova Group PLC
Robert Miller, Chief Executive
01993 880 700
Nominated adviser:
Nabarro Wells & Co. Limited
Marc Cramsie/John Wilkes
020 7710 7400
Broker:
J M Finn & Co. Limited
Sam Smith
020 7628 9688
Media enquiries
Abchurch Communications
Peter Laing/Ashley Tapp/Stephanie Cuthbert
020 7398 7700
Stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com
Note to editors
Phynova is a UK pharmaceutical company developing prescription drugs mainly derived from Chinese botanical medicines. The Company is focused on finding treatments for viral and metabolic diseases and cancer and has a strong, broad-based pipeline of potential drugs, with lead candidates for treating Hepatitis C, obesity and cancer
The Company was established in July 2002 to address unmet therapeutic needs in the West, developing drug candidates derived from botanical medicines that have already proven to be safe and effective over many years of clinical use in China. Phynova is pioneering medicines from single plants and from formulations of extracts from different plants, to obtain novel combinations which are rich or absent in given chemicals.
Phynova has five families of patents and patent applications. The Company files new patent applications to protect its drug candidates and when appropriate also applies for plant variety rights. A plant variety right confers 25 years of exclusivity from grant to the proprietor of a new variety."
Phynova works alongside Chinese researchers, government agencies and highly regarded research institutions in Europe and China. Phynova´s management team is comprised of a number of scientists from China and major Western pharmaceutical companies, who collectively have many years of experience in both "big pharma" and the Chinese scientific community.
For more information please visit www.phynova.com
About botanical medicines
Plants are an important source for the discovery of novel pharmacologically-active compounds, with many of today´s major drugs being derived directly or indirectly from plants. Examples include:
Aspirin, based on salicin, a compound obtained from the bark of the willow tree (Salix);
Taxol, a cancer drug derived from yew trees (Taxus);
Digoxin, a drug used to treat heart disease which is derived from foxgloves (Digitalis); and Artemether, an anti-malaria drug derived from a Chinese medicinal herb (Artemisia).
In June 2004, the FDA issued the final version of the Guidance for Industry Botanical Drug Products which sets out the framework for a new category of licensed drugs. Under these guidelines, the process for approval of botanical drugs is now exactly the same as for conventional synthetic NCE pharmaceuticals.
END
11/06/2007
<< Back | See all current Press releses